Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren P Mason

Showing results (21-30 of 116) with videos related to

Pageof 12
Sort By:
Neuro-Oncology Practice|May 23, 2022
First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3-PCV or temozolomide?Matthijs van der Meulen, Warren P Mason
The New England Journal of Medicine|June 1, 2017
Radiation plus Temozolomide in Patients with GlioblastomaJames R Perry, Normand Laperriere, Warren P Mason
Expert Review of Anticancer Therapy|November 10, 2009
Low-grade oligodendroglioma: current treatments and future hopesZarnie Lwin, Hui K Gan, Warren P Mason
CNS Oncology|July 24, 2014
Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient managementSolmaz Sahebjam, Mairéad G McNamara, Warren P Mason
Expert Review of Neurotherapeutics|April 22, 2016
A critical balance: managing coagulation in patients with gliomaErin R Morgan, Warren P Mason, Catherine Maurice
Cancers|November 9, 2013
Emerging biomarkers in glioblastomaMairéad G McNamara, Solmaz Sahebjam, Warren P Mason
Journal of Neuro-Oncology|February 11, 2010
Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebriMatthew K Knox, Cynthia Ménard, Warren P Mason
Current Treatment Options in Neurology|January 25, 2013
Anaplastic oligodendroglioma: advances and treatment optionsMairéad G McNamara, Solmaz Sahebjam, Warren P Mason
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|August 29, 2023
The Value of Etoposide for Recurrent GliomaMatthijs van der Meulen, Manik Chahal, Warren P Mason
CNS Oncology|December 16, 2017
Contemporary management of high-grade gliomasHao-Wen Sim, Erin R Morgan, Warren P Mason
Pageof 12

Showing results (21-30 of 116) with videos related to

Sort By:
Pageof 12
Neuro-Oncology Practice|May 23, 2022
First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3-PCV or temozolomide?Matthijs van der Meulen, Warren P Mason
The New England Journal of Medicine|June 1, 2017
Radiation plus Temozolomide in Patients with GlioblastomaJames R Perry, Normand Laperriere, Warren P Mason
Expert Review of Anticancer Therapy|November 10, 2009
Low-grade oligodendroglioma: current treatments and future hopesZarnie Lwin, Hui K Gan, Warren P Mason
CNS Oncology|July 24, 2014
Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient managementSolmaz Sahebjam, Mairéad G McNamara, Warren P Mason
Expert Review of Neurotherapeutics|April 22, 2016
A critical balance: managing coagulation in patients with gliomaErin R Morgan, Warren P Mason, Catherine Maurice
Cancers|November 9, 2013
Emerging biomarkers in glioblastomaMairéad G McNamara, Solmaz Sahebjam, Warren P Mason
Journal of Neuro-Oncology|February 11, 2010
Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebriMatthew K Knox, Cynthia Ménard, Warren P Mason
Current Treatment Options in Neurology|January 25, 2013
Anaplastic oligodendroglioma: advances and treatment optionsMairéad G McNamara, Solmaz Sahebjam, Warren P Mason
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|August 29, 2023
The Value of Etoposide for Recurrent GliomaMatthijs van der Meulen, Manik Chahal, Warren P Mason
CNS Oncology|December 16, 2017
Contemporary management of high-grade gliomasHao-Wen Sim, Erin R Morgan, Warren P Mason
Pageof 12